



ASX Release

APPENDIX 4C – QUARTERLY CASH FLOW REPORT – MARCH 2016

Melbourne, Australia, Friday 29th April 2016: Avexa Limited (ASX: AVX) lodges the attached Appendix 4C Quarterly Consolidated Statement of Cash Flows for the period ending 31 March 2016.

Commentary is provided as follows:

- The Company held cash reserves of \$0.9 million at 31 March 2016;
- The acquisition of TALI Health Pty Ltd was settled on the 15th of February 2016 through the issue of 27,584,420 shares (valued \$1.1 million); and
- The Company raised a total of \$874,000 from a Private Placement to professional and sophisticated investors and from the Share Purchase Plan (SSP) during the March quarter. These proceeds will be applied towards product development of TALI, associated TORUS Games enhancements, clinical trials and workshops and an initial rollout in targeted centres of TALI as described to shareholders at the 2015 AGM.

About Avexa Limited

Avexa is a Melbourne based medical technology company with a long history of innovation, development and commercialisation of medical treatments. Avexa's flagship program is the revolutionary and innovative TALI system, which uses a cognitive function approach to diagnosing and treating developmental disabilities including childhood attention deficits.

About TALI Health Pty Ltd (100% owned by Avexa)

TALI Health has the exclusive global license and right to acquire the TALI Technology, and is seeking to position itself as the global leader in the diagnosis and treatment of intellectual disabilities, via the unique cognitive abilities focused on in the TALI Process.

The TALI Process is a result of ground-breaking research pioneered over twenty years by internationally renowned Professor Kim Cornish, Head of School of Psychological Sciences at Monash University and her team. A collaboration between Monash University, Grey Innovation Pty Ltd and Torus Games Pty Ltd, developed the solution in response to the perceived absence of holistic approaches by the medical industry in addressing the limited awareness and treatment of intellectual disabilities, including Autism, in modern society.

The front end of the TALI Process is an attention measuring and training game (accessed by downloading an "App") for delivering interventions on tablets (or similar). The back end of the TALI Process is a Cloud based, centralised secure data collection, analysis and report back function.

For more information:

Iain Kirkwood
Executive Chairman
Mob: +61 408 473 496
Avexa: +61 3 8888 1040

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Name of entity

AVEXA LIMITED

ABN

53 108 150 750

Quarter ended ("current quarter")

31 March 2016

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Cumulative to 31 Mar 2016 - \$A'000
1.1 Receipts from customers	-	-
1.2 Payments for:		
(a) Staff costs	(128)	(402)
(b) Advertising and marketing	-	(20)
(c) Research and development	(124)	(133)
(d) Leased assets	(8)	(14)
(e) Laboratory consumables	-	-
(f) Occupancy	(31)	(87)
(g) Consulting	(11)	(50)
(h) Legal and professional	(28)	(209)
(i) Corporate administration	(11)	(77)
(j) Travel and entertainment	(5)	(11)
(k) Insurance	-	(61)
(l) Intellectual property	(1)	(93)
(m) Other working capital	(14)	(24)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	2	9
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other - GST refunds/payments	(6)	(16)
- Government grants	-	289
- Support services	-	-
Net operating cash flows	(365)	(899)

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Cumulative to 31 Mar 2016 - \$A'000
1.8 Net operating cash flows (carried forward)	(365)	(899)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(1)	(1)-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	(70)
1.12 Loans repaid by other entities	-	-
1.13 Other: Proceeds on acquisition of TALI	55	55
Net investing cash flows	54	(16)
1.14 Total operating and investing cash flows	(311)	(915)
Cash flows related to financing activities		
1.15 Net proceeds from issues of shares, options, etc. net of raising costs	827	812
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings		
1.19 Dividends paid	-	-
1.20 Other:	-	-
Net financing cash flows	827	812
Net increase (decrease) in cash held	516	(103)
1.21 Cash at beginning of quarter/year to date	406	1,025
1.22 Exchange rate adjustments to item 1.21	(1)	(1)
1.23 Cash at end of quarter	921	921

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Cumulative to 31 Mar 2016 - \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	53
1.25	Aggregate amount of loans to the parties included in item 1.11	70

1.26 Explanation necessary for an understanding of the transactions

Cash payments to directors comprise non-executive director fees for the quarter.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

On 15th February 2016 the Group announced that it had completed the acquisition of TALI Health Pty Ltd as approved by shareholders at the Company's AGM on 26th November 2015. Settlement was effected through the issue of 27,584,420 ordinary shares which was valued as at 15th February 2016 at \$1.1 million.

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Not applicable.

Financing facilities available

Add notes as necessary for an understanding of the position.

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	None	Not applicable
3.2 Credit standby arrangements	None	Not applicable
3.3 Credit card facility	Nil	Nil
3.4 Bank Guarantee	31	Nil

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	120	147
4.2 Deposits at call / Term Deposits	801	259
4.3 Bank overdraft	-	-
4.4 Other (provide details):	-	-
Total: cash at end of quarter (item 1.23)	921	406

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	TALI Health Pty Ltd	None
5.2 Place of incorporation or registration	Hawthorn East, Victoria 3123	Not applicable
5.3 Consideration for acquisition or disposal	27,584,420 shares issued and valued at \$1.1 million. No cash consideration.	Not applicable
5.4 Total net assets	\$513,000	Not applicable
5.5 Nature of business	Medical technology research and development for commercialisation.	Not applicable

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.



Mr Iain Kirkwood
Director

Date: 29 April 2016

+ See chapter 19 for defined terms.